Reaction Details Report a problem with these data
Target
Galectin-1
Ligand
BDBM468289
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
1200±n/a nM
Citation
 Leffler, H; Nilsson, U; Zetterberg, F Hybrid galactoside inhibitor of galectins US Patent  US10800804 Publication Date 10/13/2020 
Target
Name:
Galectin-1
Synonyms:
14 kDa lectin | Galaptin | HPL | LEG1_HUMAN | LGALS1 | Lactose-binding lectin 1 | Lectin galactoside-binding soluble 1 | Putative MAPK-activating protein PM12
Type:
beta galactoside-binding protein
Mol. Mass.:
14713.53
Organism:
Homo sapiens (Human)
Description:
P09382
Residue:
135
Sequence:
MACGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD
  
Inhibitor
Name:
BDBM468289
Synonyms:
3′-{4-[(Butylamino)carbonyl]-1H-1,2,3-triazol-1-yl}-3′deoxy-3-O-[(5,6-difluoro-2-oxo-3-chromenyl)methyl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example S8c
Type:
Small organic molecule
Emp. Form.:
C29H36F2N4O12S
Mol. Mass.:
702.678
SMILES:
CCCCNC(=O)c1cn(nn1)[C@H]1[C@@H](O)C(CO)O[C@@H](SC2O[C@H](CO)C(O)C(OCc3cc4c(F)c(F)ccc4oc3=O)[C@H]2O)C1O |r|
Structure:
Search PDB for entries with ligand similarity: